Genworth Financial drops into this week with its own CEO selling stock at the highs, short interest climbing steadily, and options positioning suddenly more cautious — a cluster of signals that cuts against the analyst community's still-bullish stance.
The most telling data point is in the insider register. CEO Thomas McInerney sold 100,000 shares on September 3 at $10.53, a discretionary open-market sale worth just over $1 million and filed without a 10b5-1 plan. That follows an earlier $927,000 sale by McInerney in May at $9.27, and a $396,000 open-market sale by General Counsel Gregory Karawan in August. Net insider activity over the past 90 days clocks in at minus 154,708 shares for a combined loss of roughly $1.6 million in notional value. None of the recent sales were pre-scheduled. That is worth noting against a backdrop where the stock has drifted to $10.01, down 3.9% on the week and 5.6% on Tuesday alone.
Options positioning has shifted in the same direction. The put/call ratio jumped to 0.27 on Monday — well above its 20-day average of 0.22 and running nearly 1.7 standard deviations above that mean. That is not an extreme reading on its own, but the move was abrupt: PCR had barely budged from 0.21 for most of the past two weeks before spiking on the day the stock fell sharply. Borrow conditions remain entirely relaxed — availability is essentially unlimited, with hundreds of millions of shares still available to lend and a cost to borrow barely above 0.5%. There is no meaningful squeeze pressure here. Short interest at 2.4% of free float is low in absolute terms, though it has risen 10% both over the past week and the past month, drifting higher as the stock has weakened.
The Street remains constructive but has trimmed its expectations. Keefe, Bruyette & Woods analyst Ryan Krueger — the sole active voice in the analyst record — lowered his price target to $11.50 from $12.00 yesterday while holding his Outperform rating. That target still implies roughly 15% upside from current levels, but the direction of travel has reversed after a string of upgrades that took his target from $8.50 in May 2025 all the way to $12.00 in July. The bull case centres on Enact's 17% mortgage insurance market share, ROEs of 11–13%, and a balance sheet that has shed over $1.9 billion in debt since 2020. The bear case is harder to dismiss: Genworth still carries an $850 million AXA liability for pre-2005 mis-selling, and ongoing legal uncertainty is a genuine drag on the re-rating story. On valuation, the stock trades at roughly 2.7x trailing earnings — optically cheap, though the company's growth profile is weak, with five-year EBIT declining at nearly a 12% annual rate.
Institutional ownership offers modest comfort. BlackRock holds close to 15% and added shares through August. FMR added over 2.2 million shares in the most recent filing period. Donald Smith, a deep-value specialist sitting at just under 6%, made no change to its position as of June. Vanguard's various arms together hold around 11% but have been mixed — one Vanguard entity trimmed over 1.2 million shares in the June quarter. The activist register carries no 13D filers; all five-percent-plus holders are passive. Stakes are as-last-disclosed around the 5% threshold, and a holder dropping below that level may not file again.
The next earnings date is November 4. Prior prints have produced muted immediate reactions — the last two showed next-day moves of flat to down 1%, with modest recoveries over the following week. The setup heading into that date — a CEO selling at the top, short interest quietly building, options hedges rising, and the sole analyst trimming his target the same day the stock drops 5% — is worth monitoring closely as Q3 results approach.
See the live data behind this article on ORTEX.
Open GNW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
